We are happy to announce that Dr. Christine Lovly, previously deputy editor of My Cancer Genome, will become the new co-editor-in-chief. Dr. Lovly received a B.A. in chemistry from Johns Hopkins University followed by M.D. and Ph.D. degrees as part of the Medical Scientist Training Program at Washington University in St. Louis, MO. She started on faculty at Vanderbilt in the Department of Medicine, Division of Hematology-Oncology, and in Cancer Biology, in July 2012 after completing her internal medicine residency and medical oncology subspecialty training at Vanderbilt. Dr. Lovly has been involved with the planning, design, and content of MyCancerGenome.org since its inception in 2011. She is the section editor of the lung cancer, melanoma, and molecular medicine sections, as well as a contributor to the inflammatory myofibroblastic tumor (IMT) section. Dr. Lovly recently received the Damon Runyon Clinical Investigator Award for her work developing novel treatment strategies for ALK-positive lung cancer.
Co-founder and co-editor-in-chief Dr. William Pao has accepted the position of Global Head of the Oncology Disease and Translational Area in the Oncology Division of Pharmaceutical Research and Early Development at Roche in Basel, Switzerland, effective May 1st. Dr. Pao will maintain an academic affiliation with Vanderbilt’s Division of Hematology/Oncology in the Department of Medicine and the Vanderbilt-Ingram Cancer Center but will have to step down from his duties at My Cancer Genome.
Dr. Mia Levy will continue in her role as co-editor-in-chief, and My Cancer Genome will maintain its focus on developing new content and features by working with contributors, collaborators, and developing partnerships. My Cancer Genome's mission will continue to be serving cancer patients by enabling them, their doctors, and cancer researchers to quickly access up-to-date information about treatments and clinical trials available to patients based on their tumor genetic profiles.